Afam Capital Inc. increased its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 3.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 46,108 shares of the medical equipment provider’s stock after purchasing an additional 1,679 shares during the period. Afam Capital Inc.’s holdings in Zimmer Biomet were worth $5,399,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in Zimmer Biomet by 4.1% during the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after acquiring an additional 679,080 shares during the last quarter. Vanguard Group Inc. raised its stake in Zimmer Biomet by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after acquiring an additional 339,106 shares during the last quarter. Longview Partners Guernsey LTD raised its stake in Zimmer Biomet by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after acquiring an additional 1,128,973 shares during the last quarter. Nordea Investment Management AB raised its stake in Zimmer Biomet by 7.3% during the 3rd quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock valued at $617,961,000 after acquiring an additional 357,302 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Zimmer Biomet by 8.1% during the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after acquiring an additional 311,654 shares during the last quarter. 86.24% of the stock is owned by institutional investors and hedge funds.

ZBH has been the subject of several analyst reports. SunTrust Banks set a $136.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Royal Bank of Canada reduced their price objective on Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. Morgan Stanley reduced their price objective on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. BMO Capital Markets reduced their price objective on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, November 2nd. Finally, Deutsche Bank raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research note on Tuesday, November 14th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $133.71.

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) traded up $0.13 during mid-day trading on Tuesday, hitting $113.51. The stock had a trading volume of 1,144,900 shares, compared to its average volume of 1,355,405. The stock has a market cap of $22,956.40, a P/E ratio of 14.05, a price-to-earnings-growth ratio of 1.76 and a beta of 1.15. Zimmer Biomet Holdings Inc has a fifty-two week low of $100.81 and a fifty-two week high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the company posted $1.79 earnings per share. analysts expect that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Afam Capital Inc. Boosts Stake in Zimmer Biomet Holdings Inc (ZBH)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/12/afam-capital-inc-boosts-stake-in-zimmer-biomet-holdings-inc-zbh.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related stocks with our FREE daily email newsletter.